<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">513</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2021-20-2-111-120</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Nodular lymphocyte-predominant Hodgkin Lymphoma in children. Retrospective clinical and morphological analysis of the patients. One Center experience</article-title><trans-title-group xml:lang="ru"><trans-title>Клинико-морфологические характеристики нодулярной лимфомы Ходжкина с лимфоцитарным преобладанием у детей. Опыт одного Центра</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9921-5620</contrib-id><name-alternatives><name xml:lang="en"><surname>Senchenko</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Сенченко</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Samory Mashela St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997, Москва, ул. Саморы Машела, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3664-2876</contrib-id><name-alternatives><name xml:lang="en"><surname>Abramov</surname><given-names>D. S.</given-names></name><name xml:lang="ru"><surname>Абрамов</surname><given-names>Д. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dmitry S. Abramov, MD, pathologist, Pathology Department, 1 Samory Mashela St., Moscow 117997</p></bio><bio xml:lang="ru"><p>Абрамов Дмитрий Сергеевич, врач-патологоанатом патологоанатомического отделения 117997, Москва, ул. Саморы Машела, 1</p></bio><email>dmitry.abramov@fccho-moscow.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4978-0496</contrib-id><name-alternatives><name xml:lang="en"><surname>Nasirdinova</surname><given-names>G. A.</given-names></name><name xml:lang="ru"><surname>Насирдинова</surname><given-names>Г. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Samory Mashela St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997, Москва, ул. Саморы Машела, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2574-1636</contrib-id><name-alternatives><name xml:lang="en"><surname>Volchkov</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Волчков</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Samory Mashela St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997, Москва, ул. Саморы Машела, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7732-8184</contrib-id><name-alternatives><name xml:lang="en"><surname>Konovalov</surname><given-names>D. M.</given-names></name><name xml:lang="ru"><surname>Коновалов</surname><given-names>Д. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Samory Mashela St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997, Москва, ул. Саморы Машела, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4779-1896</contrib-id><name-alternatives><name xml:lang="en"><surname>Myakova</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Мякова</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Samory Mashela St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997, Москва, ул. Саморы Машела, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare &#13;
of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-05-22" publication-format="electronic"><day>22</day><month>05</month><year>2021</year></pub-date><volume>20</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>111</fpage><lpage>120</lpage><history><date date-type="received" iso-8601-date="2021-05-21"><day>21</day><month>05</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-05-21"><day>21</day><month>05</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/513">https://hemoncim.com/jour/article/view/513</self-uri><abstract xml:lang="en"><p>Lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a unique variant of Hodgkin's lymphoma (LH) with a relatively good prognosis. The tumor differs markedly from classic LH and is one of the forms B cell lymphoma. Despite the indolent course, it has a tendency to multiple and often late relapses. Microscopically, the tumor has 6 distinguishable morphological patterns. Despite the prevalence in all age groups, most of the original studies were performed among adult patients, while there are only several publications among the children's population. The aim of this study – retrospective analysis pediatric group of the NLPHL, evaluate the prognostic implication of histopathologic variants. Сomparing our own data with another study groups. This study is supported by the Independent Ethics Committee and approved by the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Study was included the biopsies aged 3 to 18 years (median 10.5 years) of 28 patients with NLPHL from the archive by Department of Pathology Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from 2014 to 2020. The tumor more commonly affects males (20 boys and 8 girls, male-female ratio, 2.5:1). Complete clinical information was available in 24 patients. The clonal molecular assays were performed in 2 cases of relapse/progression of the disease. The Fisher's exact test was used to compare and evaluate the statistical significance of the differences in groups of patterns. There were no significant differences between typical patterns and variants, probably due to the small number of the patients. Further research will create a predictive scale for stratification by the risk groups. In cases of poor response to therapy, there is a risk that the pattern will turn into a prognostically more unfavorable variant.</p></abstract><trans-abstract xml:lang="ru"><p>Нодулярная лимфома Ходжкина с лимфоцитарным преобладанием (НЛХЛП) – отдельный вариант лимфомы Ходжкина (ЛХ) с относительно хорошим прогнозом. Опухоль заметно отличается от классической ЛХ и является одной из форм В-клеточной лимфомы, несмотря на индолентное течение, имеет склонность к множественным и часто поздним рецидивам. Выделяют 6 морфологических паттернов. На сегодняшний день продолжаются исследования, направленные на поиск прогностического значения паттернов НЛХЛП. Несмотря на распространенность во всех возрастных группах, большая часть оригинальных исследований выполнена среди взрослых пациентов, тогда как среди детской популяции публикации по данной теме единичны. Мы провели ретроспективный анализ собственных наблюдений НЛХЛП у детей с целью сравнительной оценки иммуноархитектурных паттернов и выявления возможных взаимосвязей между видом паттерна и клиническим течением заболевания и сравнили полученные результаты с данными литературы. Данное исследование одобрено независимым этическим комитетом и утверждено решением ученого совета ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России. В исследование были включены 28 пациентов с первичной или рецидивной НЛХЛП (20 мальчиков и 8 девочек) в возрасте от 3 до 18 лет (медиана 10,5 года). Полная клиническая информация была доступна у 24 пациентов. В 2 случаях рецидива/прогрессии проведено определение клональных перестроек генов иммуноглобулинов и Т-клеточного рецептора с помощью высокопроизводительного секвенирования (next generation sequencing, NGS). Для сравнения и оценки статистической значимости различий в группах паттернов применялся точный тест Фишера. Распространенность заболевания составила 3,9% среди всех диагностированных случаев ЛХ в НМИЦ ДГОИ им Дмитрия Рогачева. У 18 (75%) человек при инициальном обследовании была установлена I–II стадия, у 5 (20,8%) – III стадия, у 1 (4,2%) – IV стадия. Среди морфологических паттернов отмечалось преобладание паттерна А (n= 16; 57,1%), вторым по частоте был паттерн С (n= 6; 21,4%), третьим – паттерн F (n= 5; 17,9%) и 1 (3,6%) случай представлен паттерном В. Рецидив возник у 2 пациентов с IA стадией (паттерны С и А/С) после хирургического лечения в объеме эксцизионной биопсии без дополнительного проведения химио- или лучевой терапии через 2,5 мес и 3 года соответственно, в последнем случае также произошла смена паттерна на более неблагоприятный (А/C на С). Случаев трансформации в диффузную крупноклеточную В-клеточную лимфому выявлено е было. На момент написания статьи все пациенты находились в ремиссии. Значимых различий между клиническими особенностями и течением болезни в случаях с различными гистологическими паттернами выявлено не было, вероятно, вследствие небольшого числа пациентов. В 2 случаях мы наблюдали изменение паттерна, в одном – на фоне химиотерапии, во втором – после хирургического лечения без химиотерапии. Продолжение исследования с накоплением и расширением когорты пациентов позволит выявить прогностическое значение паттернов у детей, что может стать одним из критериев будущей шкалы стратификации групп риска у детей в целях подбора терапии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Hodgkin's lymphoma</kwd><kwd>nodular lymphocytic-predominant Hodgkin's lymphoma</kwd><kwd>childhood lymphomas</kwd><kwd>lymphoma</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лимфома Ходжкина</kwd><kwd>нодулярная лимфома Ходжкина с лимфоцитарным преобладанием</kwd><kwd>детские лимфомы</kwd><kwd>лимфома</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Swerdlow S.H., Campo E., Harris N.L. World Health Organization classification of haematopoetic and lymphoid tissues. Lyon: IARC Press; 2017. Рp. 323–325.</mixed-citation><mixed-citation xml:lang="ru">Swerdlow S.H., Campo E., Harris N.L. World Health Organization classification of haematopoetic and lymphoid tissues. Lyon: IARC Press; 2017. Рp. 323–325.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Shankar A.G., Kirkwood A.A., Hall G.W., Hayward J., O'Hare P., Ramsay A.D. Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma - A review of clinical outcome based on the histological variants. Br J Haematol 2015; 171 (2): 254–62. DOI: 10.1111/bjh.13540. Epub 2015 Jun 2.</mixed-citation><mixed-citation xml:lang="ru">Shankar A.G., Kirkwood A.A., Hall G.W., Hayward J., O'Hare P., Ramsay A.D. Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma - A review of clinical outcome based on the histological variants. Br J Haematol 2015; 171 (2): 254–62. DOI: 10.1111/bjh.13540. Epub 2015 Jun 2.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Murphy S.B., Morgan E.R., Katzenstein H.M., Kletzel M. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 2003; 25 (9): 684–7. DOI: 10.1097/00043426-200309000-00003. PMID: 12972802.</mixed-citation><mixed-citation xml:lang="ru">Murphy S.B., Morgan E.R., Katzenstein H.M., Kletzel M. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 2003; 25 (9): 684–7. DOI: 10.1097/00043426-200309000-00003. PMID: 12972802.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Hall G.W., Katzilakis N., Pinkerton C.R., Nicolin G., Ashley S., Shankar А., et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma – a Children's Cancer and Leukaemia Group report. Br J Haematol 2007; 138 (6): 761–8. DOI: 10.1111/j.1365-2141.2007.06736.x</mixed-citation><mixed-citation xml:lang="ru">Hall G.W., Katzilakis N., Pinkerton C.R., Nicolin G., Ashley S., Shankar А., et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma – a Children's Cancer and Leukaemia Group report. Br J Haematol 2007; 138 (6): 761–8. DOI: 10.1111/j.1365-2141.2007.06736.x</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Mauz-Körholz C., Gorde-Grosjean S., Hasenclever D., Shankar А., Dörffel W., et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110 (1): 179–85.</mixed-citation><mixed-citation xml:lang="ru">Mauz-Körholz C., Gorde-Grosjean S., Hasenclever D., Shankar А., Dörffel W., et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110 (1): 179–85.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Pellegrino B., Terrier-Lacombe M.J., Oberlin O., Leblanc T., Perel Y., Bertrand Y., et al. Study of the French Society of Pediatric Oncology. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology. J Clin Oncol 2003; 21 (15): 2948–52.</mixed-citation><mixed-citation xml:lang="ru">Pellegrino B., Terrier-Lacombe M.J., Oberlin O., Leblanc T., Perel Y., Bertrand Y., et al. Study of the French Society of Pediatric Oncology. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology. J Clin Oncol 2003; 21 (15): 2948–52.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Mauz-Körholz C., Lange T., Hasenclever D., Burkhardt В., Feller А.С., Körholz D., et al. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. Klin Padiatr 2015; 227 (6–7): 314–21.</mixed-citation><mixed-citation xml:lang="ru">Mauz-Körholz C., Lange T., Hasenclever D., Burkhardt В., Feller А.С., Körholz D., et al. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. Klin Padiatr 2015; 227 (6–7): 314–21.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Shankar А., Hall G.W., GordeGrosjean S., Hasenclever D., Leblanc Т., Hayward J., et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an AngloFrench collaborative report. Eur J Cancer 2012;48 (11): 1700–6.</mixed-citation><mixed-citation xml:lang="ru">Shankar А., Hall G.W., GordeGrosjean S., Hasenclever D., Leblanc Т., Hayward J., et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an AngloFrench collaborative report. Eur J Cancer 2012;48 (11): 1700–6.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Shankar A.G., Kirkwood A.A., Depani S., Bianchi Е., Hayward J., Hall G.W., et al. Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents – a report from the United Kingdom's Children's Cancer and Leukaemia Study Group. Br J Haematol 2016; 173 (3): 1–31.</mixed-citation><mixed-citation xml:lang="ru">Shankar A.G., Kirkwood A.A., Depani S., Bianchi Е., Hayward J., Hall G.W., et al. Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents – a report from the United Kingdom's Children's Cancer and Leukaemia Study Group. Br J Haematol 2016; 173 (3): 1–31.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Hartmann S., Eichenauer D.A., Plütschow A., Mottok A., Bob R., Klapper W. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2013; 122 (26): 4246–52; quiz 4292. DOI: 10.1182/blood-2013-07-515825. Epub 2013 Oct 7.</mixed-citation><mixed-citation xml:lang="ru">Hartmann S., Eichenauer D.A., Plütschow A., Mottok A., Bob R., Klapper W. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2013; 122 (26): 4246–52; quiz 4292. DOI: 10.1182/blood-2013-07-515825. Epub 2013 Oct 7.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Fan Z., Natkunam Y., Bair E., Tibshirani R., Warnke R.A. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003; 27 (10): 1346–56. DOI: 10.1097/PAS.0b013e318165b0d6</mixed-citation><mixed-citation xml:lang="ru">Fan Z., Natkunam Y., Bair E., Tibshirani R., Warnke R.A. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003; 27 (10): 1346–56. DOI: 10.1097/PAS.0b013e318165b0d6</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Gloghini A., Bosco A., Ponzoni M., Spina M., Carbone A. Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications. Expert Rev Hematol 2015; 8 (2): 217–23.</mixed-citation><mixed-citation xml:lang="ru">Gloghini A., Bosco A., Ponzoni M., Spina M., Carbone A. Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications. Expert Rev Hematol 2015; 8 (2): 217–23.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Nam-Cha S.H., Roncador G., SanchezVerde L., Montes-Moreno S., Acevedo A., Domínguez-Franjo P., et al. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am J Surg Pathol 2008; 32 (8): 1252–7. DOI: 10.1097/PAS.0b013e318165b0d6. PMID: 18594468.</mixed-citation><mixed-citation xml:lang="ru">Nam-Cha S.H., Roncador G., SanchezVerde L., Montes-Moreno S., Acevedo A., Domínguez-Franjo P., et al. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am J Surg Pathol 2008; 32 (8): 1252–7. DOI: 10.1097/PAS.0b013e318165b0d6. PMID: 18594468.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Churchill H.R., Roncador G., Warnke R.A., Natkunam Y. Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis. Hum Pathol 2010; 41 (12): 1726–34. DOI: 10.1016/j.humpath.2010.05.010. Epub 2010 Sep 9. PMID: 20825974.</mixed-citation><mixed-citation xml:lang="ru">Churchill H.R., Roncador G., Warnke R.A., Natkunam Y. Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis. Hum Pathol 2010; 41 (12): 1726–34. DOI: 10.1016/j.humpath.2010.05.010. Epub 2010 Sep 9. PMID: 20825974.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Karayalcin G., Behm F.G., Gieser P.W., Kung F., Weiner M., Murphy S.B., et al. Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment – the Pediatric Oncology Group experience. Med Pediatr Oncol 1997; 29 (6): 519–25. DOI: 10.1002/(sici)1096-911x(199712)29:6&lt;519::aidmpo1&gt;3.0.co;2-n</mixed-citation><mixed-citation xml:lang="ru">Karayalcin G., Behm F.G., Gieser P.W., Kung F., Weiner M., Murphy S.B., et al. Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment – the Pediatric Oncology Group experience. Med Pediatr Oncol 1997; 29 (6): 519–25. DOI: 10.1002/(sici)1096-911x(199712)29:6&lt;519::aidmpo1&gt;3.0.co;2-n</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Biasoli I., Stamatoullas A., Meignin V., Delmer A., Reman O., Morschhauser F., et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116 (3): 631–9. DOI: 10.1002/cncr.24819</mixed-citation><mixed-citation xml:lang="ru">Biasoli I., Stamatoullas A., Meignin V., Delmer A., Reman O., Morschhauser F., et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116 (3): 631–9. DOI: 10.1002/cncr.24819</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Xing K.H., Connors J.M., Mansour M.A., Gascoyne R.D. The outcome of advanced stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) compared to classical Hodgkin lymphoma (CHL): a matched pair analysis. ASH Annual Meeting 2012 (abstract 1531).</mixed-citation><mixed-citation xml:lang="ru">Xing K.H., Connors J.M., Mansour M.A., Gascoyne R.D. The outcome of advanced stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) compared to classical Hodgkin lymphoma (CHL): a matched pair analysis. ASH Annual Meeting 2012 (abstract 1531).</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Комков А.Ю., Мирошниченкова А.М., Ольшанская Ю.В., Мякова Н.В., Дьяконова Ю.Ю., Минервина А.А. и др. Детек-ция перестроек иммуноглобулиновых генов при острых лимфобластных лейкозах с использованием высокопроиз-водительного секвенирования нового поколения. Гематология и трансфузиология 2016; 61 (4): 200–4.</mixed-citation><mixed-citation xml:lang="ru">Комков А.Ю., Мирошниченкова А.М., Ольшанская Ю.В., Мякова Н.В., Дьяконова Ю.Ю., Минервина А.А. и др. Детек-ция перестроек иммуноглобулиновых генов при острых лимфобластных лейкозах с использованием высокопроиз-водительного секвенирования нового поколения. Гематология и трансфузиология 2016; 61 (4): 200–4.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Nogová L., Reineke T., Josting A., Müller-Hermelink H.K., Eich H.T., Behringer K., et al. Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes. Eur J Haematol Suppl 2005; (66): 106–10. DOI: 10.1111/j.1600-0609.2005.00462.x. PMID: 16007877.</mixed-citation><mixed-citation xml:lang="ru">Nogová L., Reineke T., Josting A., Müller-Hermelink H.K., Eich H.T., Behringer K., et al. Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes. Eur J Haematol Suppl 2005; (66): 106–10. DOI: 10.1111/j.1600-0609.2005.00462.x. PMID: 16007877.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Huppmann A.R., Nicolae A., Slack G.W., Pittaluga S., Davies-Hill T., Ferry J.A., et al. EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults. Am J Surg Pathol 2014; 38 (3): 316–24. DOI: 10.1097/PAS.0000000000000107</mixed-citation><mixed-citation xml:lang="ru">Huppmann A.R., Nicolae A., Slack G.W., Pittaluga S., Davies-Hill T., Ferry J.A., et al. EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults. Am J Surg Pathol 2014; 38 (3): 316–24. DOI: 10.1097/PAS.0000000000000107</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Couronné L., Schneider P., Picquenot J.M., Laberge S., Bastard C., Vannier J.P. Refractory nodular lymphocyte predominant Hodgkin lymphoma transformed to T-cell/histiocyte-rich B-cell lymphoma in an adolescent: salvage therapy with allogeneic bone marrow transplantation. J Pediatr Hematol Oncol 2008; 30 (12): 959–62. DOI: 10.1097/MPH.0b013e31818a9564. PMID: 19131792.</mixed-citation><mixed-citation xml:lang="ru">Couronné L., Schneider P., Picquenot J.M., Laberge S., Bastard C., Vannier J.P. Refractory nodular lymphocyte predominant Hodgkin lymphoma transformed to T-cell/histiocyte-rich B-cell lymphoma in an adolescent: salvage therapy with allogeneic bone marrow transplantation. J Pediatr Hematol Oncol 2008; 30 (12): 959–62. DOI: 10.1097/MPH.0b013e31818a9564. PMID: 19131792.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Xu-Monette Z.Y., Li J., Xia Y., Crossley B., Bremel R.D., Young K.H., et al. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune check point blockade and neoantigen-based immunotherapies. J Immunother Cancer 2019; 7 (1): 272. DOI: 10.1186/s40425-019-0730-x. PMID: 31640780; PMCID: PMC6806565.</mixed-citation><mixed-citation xml:lang="ru">Xu-Monette Z.Y., Li J., Xia Y., Crossley B., Bremel R.D., Young K.H., et al. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune check point blockade and neoantigen-based immunotherapies. J Immunother Cancer 2019; 7 (1): 272. DOI: 10.1186/s40425-019-0730-x. PMID: 31640780; PMCID: PMC6806565.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Dunn-Walters D., Thiede C., Alpen B., Spencer J. Somatic hypermutation and B-cell lymphoma. Philos Trans R Soc Lond B Biol Sci 2001; 356 (1405): 73–82. DOI: 10.1098/rstb.2000.0751. PMID: 11205334; PMCID: PMC1087694.</mixed-citation><mixed-citation xml:lang="ru">Dunn-Walters D., Thiede C., Alpen B., Spencer J. Somatic hypermutation and B-cell lymphoma. Philos Trans R Soc Lond B Biol Sci 2001; 356 (1405): 73–82. DOI: 10.1098/rstb.2000.0751. PMID: 11205334; PMCID: PMC1087694.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
